Overview

The marketing authorisation for Thelin has been withdrawn at the request of the marketing authorisation holder.

български (BG) (442.17 KB - PDF)

View

español (ES) (349.5 KB - PDF)

View

čeština (CS) (345.47 KB - PDF)

View

dansk (DA) (286.66 KB - PDF)

View

Deutsch (DE) (351.47 KB - PDF)

View

eesti keel (ET) (285.38 KB - PDF)

View

ελληνικά (EL) (388.19 KB - PDF)

View

français (FR) (348.81 KB - PDF)

View

italiano (IT) (349.42 KB - PDF)

View

latviešu valoda (LV) (352.98 KB - PDF)

View

lietuvių kalba (LT) (316.89 KB - PDF)

View

magyar (HU) (338.56 KB - PDF)

View

Malti (MT) (406.16 KB - PDF)

View

Nederlands (NL) (285.24 KB - PDF)

View

polski (PL) (346.97 KB - PDF)

View

português (PT) (348.72 KB - PDF)

View

română (RO) (376.34 KB - PDF)

View

slovenčina (SK) (346.2 KB - PDF)

View

slovenščina (SL) (338.93 KB - PDF)

View

Suomi (FI) (287.48 KB - PDF)

View

svenska (SV) (347.88 KB - PDF)

View

Product information

български (BG) (1.06 MB - PDF)

View

español (ES) (559.73 KB - PDF)

View

čeština (CS) (850.38 KB - PDF)

View

dansk (DA) (579.58 KB - PDF)

View

Deutsch (DE) (588.47 KB - PDF)

View

eesti keel (ET) (550.62 KB - PDF)

View

ελληνικά (EL) (1.09 MB - PDF)

View

français (FR) (565.06 KB - PDF)

View

íslenska (IS) (572.14 KB - PDF)

View

italiano (IT) (582.01 KB - PDF)

View

latviešu valoda (LV) (872.17 KB - PDF)

View

lietuvių kalba (LT) (573.31 KB - PDF)

View

magyar (HU) (874.73 KB - PDF)

View

Malti (MT) (933.02 KB - PDF)

View

Nederlands (NL) (565.77 KB - PDF)

View

norsk (NO) (562.94 KB - PDF)

View

polski (PL) (881.59 KB - PDF)

View

português (PT) (577.03 KB - PDF)

View

română (RO) (551.07 KB - PDF)

View

slovenčina (SK) (878.03 KB - PDF)

View

slovenščina (SL) (844.39 KB - PDF)

View

Suomi (FI) (576.67 KB - PDF)

View

svenska (SV) (564.5 KB - PDF)

View

Latest procedure affecting product information: T/0031

06/01/2011

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (302.55 KB - PDF)

View

español (ES) (212.78 KB - PDF)

View

čeština (CS) (286.77 KB - PDF)

View

dansk (DA) (212.72 KB - PDF)

View

Deutsch (DE) (212.71 KB - PDF)

View

eesti keel (ET) (212.78 KB - PDF)

View

ελληνικά (EL) (292.68 KB - PDF)

View

français (FR) (212.8 KB - PDF)

View

italiano (IT) (221.33 KB - PDF)

View

latviešu valoda (LV) (288.52 KB - PDF)

View

lietuvių kalba (LT) (280.09 KB - PDF)

View

magyar (HU) (250.21 KB - PDF)

View

Malti (MT) (310.85 KB - PDF)

View

Nederlands (NL) (212.59 KB - PDF)

View

polski (PL) (252.43 KB - PDF)

View

português (PT) (212.8 KB - PDF)

View

română (RO) (282.96 KB - PDF)

View

slovenčina (SK) (285.63 KB - PDF)

View

slovenščina (SL) (285.94 KB - PDF)

View

Suomi (FI) (212.69 KB - PDF)

View

svenska (SV) (212.78 KB - PDF)

View

български (BG) (361.79 KB - PDF)

View

español (ES) (304.05 KB - PDF)

View

čeština (CS) (329.04 KB - PDF)

View

dansk (DA) (298.71 KB - PDF)

View

Deutsch (DE) (305.21 KB - PDF)

View

eesti keel (ET) (296.51 KB - PDF)

View

ελληνικά (EL) (366.93 KB - PDF)

View

français (FR) (303.69 KB - PDF)

View

italiano (IT) (294.48 KB - PDF)

View

latviešu valoda (LV) (332.04 KB - PDF)

View

lietuvių kalba (LT) (305.37 KB - PDF)

View

magyar (HU) (325.61 KB - PDF)

View

Malti (MT) (344.82 KB - PDF)

View

Nederlands (NL) (305.22 KB - PDF)

View

polski (PL) (337.48 KB - PDF)

View

português (PT) (299.44 KB - PDF)

View

română (RO) (301.31 KB - PDF)

View

slovenčina (SK) (333.66 KB - PDF)

View

slovenščina (SL) (326.71 KB - PDF)

View

Suomi (FI) (296.53 KB - PDF)

View

svenska (SV) (297.57 KB - PDF)

View

Product details

Name of medicine
Thelin
Active substance
sitaxentan sodium
International non-proprietary name (INN) or common name
sitaxentan sodium
Therapeutic area (MeSH)
Hypertension, Pulmonary
Anatomical therapeutic chemical (ATC) code
C02KX03

Pharmacotherapeutic group

Antihypertensives

Therapeutic indication

Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

Authorisation details

EMA product number
EMEA/H/C/000679
Marketing authorisation holder
Pfizer Ltd.

Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
10/08/2006
Revision
13

Assessment history

This page was last updated on

Share this page